No products in the cart.
#VisualAbstract AMLSG 09-09: Adding getuzumab ozogamicin (GO) to intensive therapy for Nucleophosmin1 mutated acute myeloid leukemia (NPM1mut AML) leads to better NPM1mut transcript clearance and a lower replase rate
RelatedReports
![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://2minutemedicine-wpengine.netdna-ssl.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.